Both Trametinib and Cobimetinib were approved in the last 5 years and are indicated for the treatment of BRAF mutant metastatic melanoma in order to avoid tumor relapse after surgical excision (Long et al., 2017). The gene discussed is BRAF; the disease is neoplasm.